Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies

Drug Resistance Updates

Volumn 14, Issue 6, 2011, Pages 280-296

  Crea, Francesco ^a   Nobili, Stefania ^b   Paolicchi, Elisa ^a   Perrone, Gabriele ^b   Napoli, Cristina ^b   Landini, Ida ^b   Danesi, Romano ^a   Mini, Enrico ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5 Fluorouracil; Chemoresistance; Colorectal cancer; DNA methyl transferase inhibitors; Epigenetics; Histone deacetylase inhibitors; Irinotecan; Oxaliplatin

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; FLUCYTOSINE DEOXYRIBOSIDE; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IRINOTECAN; MG 98; MOCETINOSTAT; N PHTHALOYLTRYPTOPHAN; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PANOBINOSTAT; PHOSPHOTRANSFERASE; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; TEMOZOLOMIDE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; URIDINE MONOPHOSPHATE CYTIDINE MONOPHOSPHATE KINASE; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ARTICLE; CANCER CELL; COLORECTAL CANCER; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE CONTROL; GENE SILENCING; GLIOBLASTOMA; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054084433     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2011.08.001     Document Type: Article

References (232)

1. R. Abele, M. Clavel, and P. Dodion The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas Eur. J. Cancer Clin. Oncol. 23 1987 1921 1924 (Pubitemid 18013335)
2. B.L. Adamsen, K.L. Kravik, O.P. Clausen, and P.M. De Angelis Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment Int. J. Oncol. 31 2007 1491 1500
3. O. Aguilera, M.F. Fraga, and E. Ballestar Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer Oncogene 25 2006 4116 4121 (Pubitemid 44024874)
4. A. Aparicio, C.A. Eads, and L.A. Leong Phase I trial of continuous infusion 5-aza-2′-deoxycytidine Cancer Chemother. Pharmacol. 51 2003 231 239 (Pubitemid 36469953)
5. K. Appleton, H.J. Mackay, and I. Judson Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors J. Clin. Oncol. 25 2007 4603 4609 (Pubitemid 350035319)
6. C.N. Arnold, A. Goel, and C.R. Boland Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines Int. J. Cancer 106 2003 66 73 (Pubitemid 36750389)
7. C. Aschele, A. Sobrero, M.A. Faderan, and J.R. Bertino Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules Cancer Res. 52 1992 1855 1864
8. A. Atmaca, S.E. Al-Batran, and A. Maurer Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial Br. J. Cancer 97 2007 177 182 (Pubitemid 47057472)
9. D. Banerjee, R. Gorlick, and A. Liefshitz Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase Cancer Res. 60 2000 2365 2367 (Pubitemid 30262423)
10. D. Banerjee, P. Mayer-Kuckuk, and G. Capiaux Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase Biochim. Biophys. Acta 1587 2002 164 173 (Pubitemid 34657277)
11. K.W. Barbour, S.H. Berger, and F.G. Berger Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase Mol. Pharmacol. 37 1990 515 518 (Pubitemid 20130794)
12. S.B. Baylin Resistance, epigenetics and the cancer ecosystem Nat. Med. 17 2011 288 289
13. A.S. Belanger, J. Tojcic, M. Harvey, and C. Guillemette Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells BMC Mol. Biol. 11 2010 9 20
14. S.H. Berger, K.W. Barbour, and F.G. Berger A naturally occorring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2′-deoxyuridine in a human colon tumor cell line Mol. Pharmacol. 34 1988 480 484
15. S.H. Berger, C.H. Jenh, L.F. Johnson, and F.G. Berger Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells Mol. Pharmacol. 28 1985 461 467 (Pubitemid 16224251)
16. M.M. Bertagnolli, D. Niedzwiecki, and C.C. Compton Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 J. Clin. Oncol. 27 2009 1814 1821
17. J.R. Bertino, and D. Banerjee Thymidylate synthase as an oncogene? Cancer Cell. 5 2004 301 302 (Pubitemid 38482063)
18. G.D. Birnie, H. Kroeger, and C. Heidelberger Studies of fluorinated pyrimidines, XVIII. The degradation of 5-fluoro-2'-deoxyuridine and related compounds by nucleoside phosphorylase Biochemistry 2 1963 566 572
19. C.R. Boland, and A. Goel Microsatellite instability in colorectal cancer Gastroenterology 138 2010 2073 2087
20. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discov. 5 2006 769 784 (Pubitemid 44348499)
21. F. Braiteh, A.O. Soriano, and G. Garcia-Manero Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers Clin. Cancer Res. 14 2008 6296 6301
22. H.J. Broxterman, J. Lankelma, and H.M. Pinedo How to probe clinical tumour samples for P-glycoprotein and multidrug-resistance associated protein Eur. J. Cancer 32A 1996 1024 1033
23. B. Brueckner, R. Garcia Boy, and P. Siedlecki Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Res. 65 2005 6305 6311 (Pubitemid 40994416)
24. F. Bunz, P.M. Hwang, and C. Torrance Disruption of p53 in human cancer cells alters the responses to therapeutic agents J. Clin. Invest. 104 1999 263 269
25. H. Burger, A. Zoumaro-Djayoon, and A.W. Boersma Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) Br. J. Pharmacol. 159 2010 898 908
26. H. Burger, W.J. Loos, K. Eechoute, J. Verweij, R.H. Mathijssen, and E.A. Wiemer Drug transporters of platinum-based anticancer agents and their clinical significance Drug Resist. Update 14 2011 22 34
27. A. Calascibetta, F. Contino, and S. Feo Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-Fluorouracil drug response J. Nucleic Acids 26 2010 10.4061/2010/306754
28. L.H. Camacho, J. Olson, and W.P. Tong Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors Invest. New Drugs 25 2007 131 138 (Pubitemid 46020871)
29. J.S. Carew, F.J. Giles, and S.T. Nawrocki Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy Cancer Lett. 269 2008 7 17
30. X. Chang, C.L. Monitto, and S. Demokan Identification of hypermethylated genes associated with cisplatin resistance in human cancers Cancer Res. 70 2010 2870 2879
31. S. Cheetham, M.J. Tang, F. Mesak, H. Kennecke, D. Owen, and I.T. Tai SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response Br. J. Cancer 98 2008 1810 1819 (Pubitemid 351748842)
32. E. Chu, J.L. Grem, P.G. Johnston, and C.J. Allegra New concepts for the development and use of antifolates Stem Cells 14 1996 41 46 (Pubitemid 26041419)
33. E. Chu, D.M. Koeller, and J.L. Casey Autoregulation of hum an thymidylate synthase messenger RNA translation by thymidylate synthase Proc. Natl. Acad. Sci. U.S.A. 88 1991 8977 8981 (Pubitemid 21915553)
34. J.L. Clark, S.H. Berger, A. Mittelman, and F.G. Berger Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy Cancer Treatm. Rep. 71 1987 261 265 (Pubitemid 17051726)
35. S. Copur, K. Aiba, J.C. Drake, C.J. Allegra, and E. Chu Thymidylate synthase gene amplification in human colon cancer cell lines resistano to 5-fluorouracil Biochem. Pharmacol. 49 1995 1419 1426
36. P. Corsa, S. Parisi, and A. Raguso Temozolomide and radiotherapy as first-line treatment of high-grade gliomas Tumori 92 2006 299 305 (Pubitemid 44525306)
37. F. Crea, E. Giovannetti, and F. Cortesi Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines Mol. Cancer Ther. 8 2009 1964 1973
38. D. Cunningham, W. Atkin, and H.J. Lenz Colorectal cancer Lancet 375 2010 1030 1047
39. I.J. Dahabreh, T. Terasawa, P.J. Castaldi, and T.A. Trikalinos Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer Ann. Intern. Med. 154 2011 37 49
40. P.V. Danenberg, R.J. Langenbach, and C. Heidelberger Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides Biochemistry 13 1974 926 933
41. A.J. Davis, K.A. Gelmon, and L.L. Siu Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks Invest. New Drugs 21 2003 85 97 (Pubitemid 36628488)
42. J.S. de Bono, R. Kristeleit, and A. Tolcher Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors Clin. Cancer Res. 14 2008 6663 6673
43. G. Deng, A. Chen, E. Pong, and Y.S. Kim Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression Oncogene 20 2001 7120 7127 (Pubitemid 33052206)
44. G. Deng, G.A. Song, E. Pong, M. Sleisenger, and Y.S. Kim Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor Cancer Res. 64 2004 2692 2698 (Pubitemid 38500603)
45. G. Deng, A. Nguyen, and H. Tanaka Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer Int. J. Cancer 118 2006 2999 3005
46. A.M. Di Francesco, A. Ruggiero, and R. Riccardi Cellular and molecular aspects of drugs of the future: oxaliplatin Cell. Mol. Life Sci. 59 2002 1914 1927 (Pubitemid 36015864)
47. E. Di Gennaro, F. Bruzzese, and S. Pepe Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed Cancer Biol. Ther. 8 2009 782 791
48. E. Dotor, M. Cuatrecases, and M. Martínez-Iniesta Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment J. Clin. Oncol. 24 2006 1603 1611 (Pubitemid 46638784)
49. J. Dunn, A. Baborie, and F. Alam Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy Br. J. Cancer 101 2009 124 131
50. C. Dupont, D.R. Armant, and C.A. Brenner Epigenetics: definition, mechanisms and clinical perspective Semin. Reprod. Med. 27 2009 351 357
51. D. Engelmann, and B.M. Pützer Translating DNA damage into cancer cell death-A roadmap for E2F1 apoptotic signalling and opportunities for new drug combinations to overcome chemoresistance Drug Resist. Update 13 2010 119 131
52. G. Eot-Houllier, G. Fulcrand, L. Magnaghi-Jaulin, and Ch. Jaulin Histone deacetylase inhibitors and genomic instability Cancer Lett. 274 2009 169 176
53. S. Faivre, D. Chan, R. Salinas, B. Woynarowska, and J.M. Woynarowski DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells Biochem. Pharmacol. 66 2003 225 237 (Pubitemid 36776396)
54. M.G. Fakih, G. Fetterly, and M.J. Egorin A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors Clin. Cancer Res. 16 2010 3786 3794
55. M.G. Fakih, L. Pendyala, and G. Fetterly A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer Clin. Cancer Res. 15 2009 3189 3195
56. A. Falcone, S. Ricci, and I. Brunetti Gruppo Oncologico Nord Ovest Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J. Clin. Oncol. 25 2007 1670 1676 (Pubitemid 46797946)
57. W. Fazzone, P.M. Wilson, M.J. Labonte, H.J. Lenz, and R.D. Ladner Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells Int. J. Cancer 125 2009 463 473
58. M.E. Fernández-Contreras, S. Sánchez-Prudencio, and J.J. Sánchez-Hernández Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil Int. J. Oncol. 28 2006 1303 1310
59. M. Ferracin, R. Gaf, and E. Miotto The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile J. Pathol. 214 2008 594 602 (Pubitemid 351482274)
60. S. Flis, A. Gnyszka, K. Flis, and J. Spławiński MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells Eur. J. Pharmacol. 627 2010 26 32
61. S. Flis, A. Gnyszka, I. Misiewicz-Krzemińska, and J. Spławiński Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205 Cancer Cell Int. 9 2009 1 10
62. S. Flis, A. Gnyszka, and J. Spławiński HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines Biochem. Biophys. Res. Commun. 387 2009 336 341
63. L. Fornaro, G. Masi, F. Loupakis, E. Vasile, and A. Falcone Palliative treatment of unresectable metastatic colorectal cancer Exp. Opin. Pharmacother. 11 2010 63 77
64. M. Friedkin, and D. Roberts The enzymatic synthesis of nucleosides. I. Thymidine phosphorylase in mammalian tissue J. Biol. Chem. 207 1954 245 256
65. H. Fujita, J. Kato, and J. Horii Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells Oncol. Rep. 18 2007 1129 1137
66. J.F. Gagnon, O. Bernard, L. Villeneuve, B. Tetu, and C. Guillemette Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer Clin. Cancer Res. 12 2006 1850 1858
67. J. Gilbert, S.D. Baker, and M.K. Bowling A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies Clin. Cancer Res. 7 2001 2292 2300 (Pubitemid 32751627)
68. K.B. Glaser, M.J. Staver, J.F. Waring, J. Stender, R.G. Ulrich, and S.K. Davidsen Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines Mol. Cancer Ther. 2 2003 151 163
69. R.M. Glasspool, J.M. Teodoridis, and R. Brown Epigenetics as a mechanism driving polygenic clinical drug resistance Br. J. Cancer 94 2006 1087 1092
70. Gore, L., Rothenberg, M.L., O'Bryant, C.L., et al., 2008. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14, 4517-4525.
71. M.J. Gosens, E. Moerland, and V.P. Lemmens Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer Int. J. Cancer 123 2008 1941 1949
72. S. Hauswald, J. Duque-Afonso, and M.M. Wagner Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes Clin. Cancer Res. 15 2009 3705 3715
73. C. Heidelberger, N.K. Chaudhuri, and P. Danneberg Fluorinated pyrimidines, a new class of tumour-inhibitory compounds Nature 179 1957 663 666
74. F. Hollande, J. Pannequin, and D. Joubert The long road to colorectal cancer therapy: searching for the right signals Drug Resist. Update 13 2010 44 56
75. R. Holliday Epigenetics: a historical overview Epigenetics 1 2006 76 80
76. M. Hollstein, D. Sidransky, B. Vogelstein, and C.C. Harris p53 mutations in human cancers Science 253 1991 49 53 (Pubitemid 21917115)
77. A.K. Holzer, G.H. Manorek, and S.B. Howell Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin Mol. Pharmacol. 70 2006 1390 1394 (Pubitemid 44435991)
78. N. Horie, H. Aiba, K. Oguro, H. Hojo, and K. Takeishi Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase Cell Struct. Funct. 20 1995 191 197
79. J.A. Houghton, S.J. Maroda, J.O. Phillips, and P.J. Houghton Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenograft of human colorectal adenocarcinomas in mice Cancer Res. 41 1981 144 149 (Pubitemid 11218808)
80. J.A. Houghton, P.M. Torrance, S. Radparvar, L.G. Williams, and P.J. Houghton Binding of 5-fluorodeoxyuridylate to thymidylate synthase in human colon adenocarcinoma xenografts Eur. J. Cancer Clin. Oncol. 22 1986 505 510 (Pubitemid 16113811)
81. S.B. Howell, R. Safaei, C.A. Larson, and M.J. Sailor Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs Mol. Pharmacol. 77 2010 887 894
82. C.H. Hsu, J.Y. Liou, G.E. Dutschman, and Y.C. Cheng Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium Mol. Pharmacol. 67 2005 806 814 (Pubitemid 40365328)
83. R. Humeniuk, L.G. Menon, and P.J. Mishra Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance Mol. Cancer Ther. 8 2009 1037 1044
84. R. Humeniuk, P.J. Mishra, J.R. Bertino, and D. Banerjee Epigenetic reversal of acquired resistance to 5-fluorouracil treatment Mol. Cancer Ther. 8 2009 1045 1054
85. Huo, H., Magro, P.G., Pietsch, E.C., Patel, B.B., Scotto, K.W., 2010. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 70, 8726-8735.
86. F. Innocenti, D.L. Kroetz, and E. Schuetz Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics J. Clin. Oncol. 27 2009 2604 2614
87. M.H. Iltzsch, M.H. el Kouni, and S. Cha Kinetic studies of thymidine phosphorylase from mouse liver Biochemistry 24 1985 6799 6807 (Pubitemid 16170208)
88. J.P. Issa Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection Nat. Clin. Pract. Oncol. 2 Suppl. 1 2005 S24 S29
89. L. Iyer, C.D. King, and P.F. Whitington Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J. Clin. Invest. 101 1998 847 854 (Pubitemid 28096082)
90. F.V. Jacinto, E. Ballestar, S. Ropero, and M. Esteller Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells Cancer Res. 67 2007 11481 11486
91. J.R. Jass Classification of colorectal cancer based on correlation of clinical, morphological and molecular features Histopathology 50 2007 113 130 (Pubitemid 44953403)
92. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E.M.E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
93. P.G. Johnston, E.R. Fisher, and H.E. Rockette The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer J. Clin. Oncol. 12 1994 2640 2647 (Pubitemid 24379651)
94. P.A. Jones, and S.M. Taylor Cellular differentiation, cytidine analogs and DNA methylation Cell 20 1980 85 93 (Pubitemid 10117303)
95. R. Jover, T.P. Nguyen, and L. Pérez-Carbonell 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer Gastroenterology 140 2011 1174 1181
96. B. Kaina, K. Ochs, and S. Grosch BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis Prog. Nucleic Acid Res. Mol. Biol. 68 2001 41 54 (Pubitemid 33804651)
97. M.F. Kane, M. Loda, and G.M. Gaida Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines Cancer Res. 57 1997 808 811 (Pubitemid 27097998)
98. S. Kaneda, K. Takeishi, D. Ayusawa, K. Shimizu, T. Seno, and S. Altman Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA Nucleic Acids Res. 15 1987 1259 1270 (Pubitemid 17012904)
99. K. Kawakami, D. Salonga, and J.M. Park Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression Clin. Cancer Res. 7 2001 4096 4101 (Pubitemid 34044633)
100. W.K. Kelly, J. DeBono, and G. Blumenschein Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors Proc. Am. Soc. Clin. Oncol. 28 2009 3531 (abstract)
101. W.K. Kelly, O.A. O'Connor, and L.M. Krug Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J. Clin. Oncol. 23 2005 3031 3923
102. T.K. Kelly, D.D. De Carvalho, and P.A. Jones Epigenetic modifications as therapeutic targets Nat. Biotechnol. 28 2010 1069 1078
103. Y. Kidani, K. Inagaki, M. Iigo, A. Hoshi, and K. Kuretani Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascites form J. Med. Chem. 21 1978 1315 1318 (Pubitemid 9093117)
104. E.A. Kidd, J. Yu, X. Li, W.D. Shannon, M.A. Watson, and H.L. McLeod Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer Clin. Cancer Res. 11 2005 2612 2619 (Pubitemid 40569461)
105. J.C. Kim, E.S. Shin, and C.W. Kim In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer Anticancer Res. 29 2009 3027 3034
106. C.H. Kohne, and H.J. Lenz Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist 14 2009 478 488
107. M. Koopman, S. Venderbosch, I.D. Nagtegaal, J.H. van Krieken, and C.J. Punt A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur. J. Cancer 45 2009 1935 1949
108. M. Koopman, S. Venderbosch, and H. van Tinteren Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomized CAIRO study Eur. J. Cancer 45 2009 1999 2006
109. K.V. Kosuri, X. Wu, L. Wang, M.A. Villalona-Calero, and G.A. Otterson An epigenetic mechanism for capecitabine resistance in mesothelioma Biochem. Biophys. Res. Commun. 391 2010 1465 1470
110. J.G. Kuhn Pharmacology of irinotecan Oncology (Williston Park) 12 1998 39 42 (Pubitemid 28518486)
111. D.M. Kweekel, H. Gelderblom, and H.J. Guchelaar Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy Cancer Treatm. Rev. 31 2005 90 105 (Pubitemid 40542888)
112. D.M. Landis, and L.A. Loeb Random sequence mutagenesis and resistance to 5-fluorouridine in human thymidylate synthases J. Biol. Chem. 273 1998 25809 25817 (Pubitemid 28475809)
113. A. Laurent, C. Nicco, and C. Chéreau Controlling tumor growth by modulating endogenous production of reactive oxygen species Cancer Res. 65 2005 948 956 (Pubitemid 40216456)
114. J.H. Lee, J.H. Park, and Y. Jung Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol. Cancer Ther. 5 2006 3085 3095 (Pubitemid 46092050)
115. A.J. Levine, M.E. Perry, and A. Chang The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis Br. J. Cancer 69 1994 409 416 (Pubitemid 24076454)
116. J.T. Liang, K.J. Chang, and J.C. Chen Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival Oncology 57 1999 149 156
117. J. Lin, J. Gilbert, and M.A. Rudek A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors Clin. Cancer Res. 15 2009 6241 6249
118. L.F. Lincz, F.E. Scorgie, M.B. Garg, and S.P. Ackland Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele Int. J. Cancer 120 2007 1930 1934 (Pubitemid 46418369)
119. A. Lockshin, and P.V. Danenberg Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase Biochem. Pharmacol. 30 1981 247 257 (Pubitemid 11210738)
120. P.L. Lomen, L.H. Baker, G.L. Neil, and M.K. Samson Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days Cancer Chemother. Rep. 59 1975 1123 1126
121. D.B. Longley, W.L. Allen, and P.G. Johnston Drug resistance, predictive markers and pharmacogenomics in colorectal cancer Biochim. Biophys. Acta 1766 2006 184 196
122. D.B. Longley, D.P. Harkin, and P.G. Johnston 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3 2003 330 338 (Pubitemid 37328853)
123. S.W. Lowe, E. Cepero, and G. Evan Intrinsic tumour suppression Nature 432 2004 307 315 (Pubitemid 39551658)
124. F. Lyko, and R. Brown DNA methyltransferase inhibitors and the development of epigenetic cancer therapies J. Natl. Cancer Inst. 97 2005 1498 1506 (Pubitemid 41631949)
125. M.V. Mandola, J. Stoehlmacher, and S. Muller-Weeks A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity Cancer Res. 63 2003 2898 2904 (Pubitemid 36667162)
126. E. Martinez-Balibrea, A. Martínez-Cardús, and E. Musulén Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy Int. J. Cancer 124 2009 2905 2910
127. M. Malet-Martino, P. Jolimaitre, and R. Martino The prodrugs of 5-fluorouracil Curr. Med. Chem. Anticancer Agents 2 2002 267 310 (Pubitemid 34649876)
128. S. Marsh, and J.M. Hoskins Irinotecan pharmacogenomics Pharmacogenomics 11 2010 1003 1010
129. G. Mathe, Y. Kidani, and M. Segiguchi Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum Biomed. Pharmacother. 43 1989 237 250 (Pubitemid 19153975)
130. L.A. Mathews, F. Crea, and W.L. Farrar Epigenetic gene regulation in stem cells and correlation to cancer Differentiation 78 2009 1 17
131. M. Mellai, V. Caldera, and L. Annovazzi MGMT promoter hypermethylation in a series of 104 glioblastomas Cancer Genom. Proteom. 6 2009 219 227
132. R.W. McClard, M.J. Black, L.R. Livingstone, and M.E. Jones Isolation and initial characterization of the single polypeptide that synthesizes uridine 5'-monophosphate from orotate in Ehrlich ascites carcinoma. Purification by tandem affinity chromatography of uridine-5'-monophosphate synthase Biochemistry 19 1980 4699 4706 (Pubitemid 11193992)
133. McDermott, U., Longley, D.B., Galligan, L., et al., 2005. Effect of p53 status and STAT1 on chemotherapy induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 65, 8951-8960. (Pubitemid 41377386)
134. R. Metzger, K. Danenberg, and C.G. Leichman High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil Clin. Cancer Res. 4 1998 2371 2376 (Pubitemid 28477901)
135. E. Mini, F. Trave, Y.M. Rustum, and J.R. Bertino Enhancement of the antitumor effects of 5-fluorouracil by folinic acid Pharmacol. Ther. 47 1990 1 19 (Pubitemid 20183305)
136. J.L. Misset, H. Bleiberg, W. Sutherland, M. Bekradda, and E. Cvitkovic Oxaliplatin clinical activity: a review Crit. Rev. Oncol. Hematol. 35 2000 75 93 (Pubitemid 30599431)
137. C.G. Moertel, A.J. Schutt, R.J. Reitemeier, and R.G. Hahn Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer Cancer Chemother. Rep. 56 1972 649 652
138. M.A. Mulkins, and C. Heidelberger Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines Cancer Res. 42 1982 965 973 (Pubitemid 12141204)
139. P. Münster, D. Marchion, and E. Bicaku Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study J. Clin. Oncol. 25 2007 1979 1985 (Pubitemid 46972780)
140. P.N. Munster, D. Marchion, and S. Thomas Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker Br. J. Cancer 101 2009 1044 1050
141. P.N. Munster, P. Petrou, and C.J. Ryan A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies Proc. Am. Soc. Clin. Oncol. 29 2010 e13140 (abstract)
142. Y.S. Na, S.M. Kim, and K.A. Jung Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts Oncol. Rep. 24 2010 1509 1514
143. NCCN Clinical Practice Guidelines in Oncology (NCCN GuidlinesTM) - Colon cancer. Version 3.2011. http://www.nccn.org/professionals/physician-gls/pdf/ colon.pdf.
144. M.A. Nelson, S. Shetty, M. Kulakodlu, C. Harley, and B. Seal A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer J. Med. Econ. 14 2011 179 186
145. E.M. Newman, J.A. Longmate, and H.J. Lenz Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine: a California Cancer Consortium study Proc. Am. Soc. Clin. Oncol. 21 2002 431 (abstract)
146. N. Nief, V. Le Morvan, and J. Robert Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel Eur. J. Cancer 43 2007 955 962 (Pubitemid 46366695)
147. S. Nobili, C. Napoli, and I. Landini Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer Int. J. Cancer 128 2011 1935 1945
148. T. Noguchi, K. Tanimoto, and T. Shimokuni Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells Clin. Cancer Res. 10 2004 7100 7107 (Pubitemid 39383062)
149. D.W. Northfelt, E. Bonnem, J. Fagerberg, D. Von Hoff, and J. Grem Belinostat (Bel) down-regulates thymidylate synthase (TS) in tumor tissue: A dose-escalation study of belinostat alone and in combination with 5-fluorouracil (FU) Gastrointest. Cancer Symp. Am. Soc. Clin. Oncol. 333 2009 (abstract)
150. M. Ocker, A. Alajati, and M. Ganslmayer The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells J. Cancer Res. Clin. Oncol. 131 2005 385 394 (Pubitemid 40674624)
151. S. Ogino, and A. Goel Molecular classification and correlates in colorectal cancer J. Mol. Diagn. 10 2008 13 27 (Pubitemid 351184831)
152. T. Ohtsuka, X.F. Liu, and Y. Koga Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer Oncogene 25 2006 1807 1811
153. Y. Oki, E. Aoki, and J.P. Issa Decitabine - bedside to bench Crit. Rev. Oncol. Hematol. 61 2007 140 152
154. C. Pasti, S. Gallois-Montbrun, and H. Munier-Lehmann Reaction of human UMP-CMP kinase with natural and analog substrates Eur. J. Biochem. 270 2003 1784 1790 (Pubitemid 36532537)
155. A. Patnaik, E.K. Rowinsky, and M.A. Villalona A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies Clin. Cancer Res. 8 2002 2142 2148 (Pubitemid 34753584)
156. A.V. Patterson, H. Zhang, and A. Moghaddam Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase Br. J. Cancer 72 1995 669 675
157. G.J. Peters, H.H. Backus, and S. Freemantle Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism Biochim. Biophys. Acta 1587 2002 194 205 (Pubitemid 34655788)
158. A. Piunti, and D. Pasini Epigenetic factors in cancer development: polycomb group proteins Future Oncol. 7 2011 57 75
159. G. Pizzorno, and R.E. Handschumacher Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines Biochem. Pharmacol. 49 1995 559 565
160. J.A. Plumb, G. Strathdee, J. Sludden, S.B. Kaye, and R. Brown Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter Cancer Res. 60 2000 6039 6044
161. R. Plummer, L. Vidal, and M. Griffin Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors Clin. Cancer Res. 15 2009 3177 3183
162. S. Popat, A. Matakidou, and R.S. Houlston Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis J. Clin. Oncol. 22 2004 529 536 (Pubitemid 41079782)
163. H.M. Prince, M.J. Bishton, and S.J. Harrison Clinical studies of histone deacetylase inhibitors Clin. Cancer Res. 15 2009 3958 3969
164. S.T. Pullarkat, J. Stoehlmacher, and V. Ghaderi Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy Pharmacogenomics J. 1 2001 65 70 (Pubitemid 33757985)
165. L. Qiao, and B.C.Y. Wong Targeting apoptosis as an approach for gastrointestinal cancer therapy Drug Resist. Update 12 2009 55 64
166. J.M. Quagliana, R.M. O'Bryan, and L. Baker Phase II study of 5-azacytidine in solid tumors Cancer Treatm. Rep. 61 1977 51 54 (Pubitemid 8100656)
167. S. Radparvar, P.J. Houghton, and J.A. Houghton Effect of 5,10-methylentetrahydrofolate on the binding of 5-fluoro-2'-deoxyuridylate to thymidilate synthase purified from a human colon adenocarcinoma xenografts Biochem. Pharmacol. 38 1989 335 342 (Pubitemid 19033346)
168. L. Rahman, D. Voeller, and M. Rahman Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme Cancer Cell 5 2004 341 351 (Pubitemid 38482070)
169. M. Ramesh, P. Ahlawat, and N.R. Srinivas Irinotecan and its active metabolite SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives Biomed. Chromatogr. 24 2010 104 123
170. J. Ramirez, M.J. Ratain, and F. Innocenti Uridine 5'-diphospho- glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy Future Oncol. 6 2010 563 585
171. E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and molecular pharmacology of oxaliplatin Mol. Cancer Ther. 1 2002 227 235
172. K.M. Redmond, T.R. Wilson, P.G. Johnston, and D.B. Longley Resistance mechanisms to cancer chemotherapy Front Biosci. 13 2008 5138 5154 (Pubitemid 351599664)
173. A.A. Ruefli, M.J. Ausserlechner, and D. Bernhard The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species Proc. Natl. Acad. Sci. U.S.A. 98 2001 10833 10838 (Pubitemid 32878706)
174. R. Safaei, and S.B. Howell Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs Crit. Rev. Oncol. Hematol. 53 2005 13 23 (Pubitemid 39656107)
175. D. Salonga, K.D. Danenberg, and M. Johnson Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase Clin. Cancer Res. 6 2000 1322 1327 (Pubitemid 30226214)
176. R. Sanguedolce, R. Alessandro, and G. De Leo Failure of detection of the tyrosine to histidine substitution at the residue 33 of thymidylate synthase in human colorectal cancer. A preliminary study Anticancer Res. 20 2000 4347 4350 (Pubitemid 32141784)
177. G. Santelli, and F. Valeriote In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides J. Natl. Cancer Inst. 64 1980 69 72 (Pubitemid 10214283)
178. D.V. Santi, C.S. McHenry, and H. Sommer Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate Biochemistry 13 1974 471 481
179. D.J. Sargent, S. Marsoni, and G. Monges Defective mismatch repair as a predictive marker.for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer J. Clin. Oncol. 28 2010 3219 3226
180. K. Sato, Y. Kitajima, A. Miyoshi, Y. Koga, and K. Miyazaki Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment Int. J. Oncol. 29 2006 429 435
181. C. Sawan, and Z. Herceg Histone modifications and cancer Adv. Genet. 70 2010 57 85
182. S. Saxonov, P. Berg, and D.L. Brutlag A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters Proc. Natl. Acad. Sci. U.S.A. 103 2006 1412 1417 (Pubitemid 43191179)
183. D.S. Schrump, M.R. Fischette, and D.M. Nguyen Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura Clin. Cancer Res. 12 2006 5777 5785 (Pubitemid 44629609)
184. G. Schwartsmann, H. Schunemann, and C.N. Gorini A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer Invest. New Drugs 18 2000 83 91 (Pubitemid 30175899)
185. E.L. Schwartz, N. Baptiste, S. Wadler, and D. Makower Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil J. Biol. Chem. 270 1995 19073 19077
186. L. Shen, P.J. Catalano, A.B. Benson 3rd, P. O'Dwyer, S.R. Hamilton, and J.P. Issa Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy Clin. Cancer Res. 13 2007 6093 6098 (Pubitemid 350075067)
187. B.I. Shnider, M. Baig, and J. Colsky A phase I study of 5-azacytidine (NSC-102816) J. Clin. Pharmacol. 16 1976 205 212
188. L.L. Siu, R. Pili, and I. Duran Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors J. Clin. Oncol. 26 2008 1940 1947
189. R. Soong, N. Shah, and M. Salto-Tellez Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy Ann. Oncol. 19 2008 915 919 (Pubitemid 351627307)
190. T. Soussi, C. Ishioka, M. Claustres, and C. Broud Locus-specific mutation databases: pitfalls and good practice based on the p53 experience Nat. Rev. Cancer 6 2006 83 90 (Pubitemid 43053654)
191. A. Sparreboom, R. Danesi, Y. Ando, J. Chan, and W.D. Figg Pharmacogenomics of ABC transporters and its role in cancer chemotherapy Drug Resist. Update 6 2003 71 84 (Pubitemid 36565766)
192. N.L. Steele, J.A. Plumb, and L. Vidal A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors Clin. Cancer Res. 14 2008 804 810 (Pubitemid 351231163)
193. D.J. Stewart, R.C. Donehower, and E.A. Eisenhauer A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly Ann. Oncol. 14 2003 766 774 (Pubitemid 36621778)
194. H. Sugita, S. Iida, and M. Inokuchi Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer Oncol. Rep. 25 2011 513 518
195. M.W. Sung, and S. Waxman Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer Anticancer Res. 27 2007 995 1001 (Pubitemid 46587012)
196. I.T. Tai, M. Dai, D.A. Owen, and L.B. Chen Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy J. Clin. Invest. 115 2005 1492 1502 (Pubitemid 40814658)
197. I.T. Tai, and M.J. Tang SPARC in cancer biology: its role in cancer progression and potential for therapy Drug Resist. Update 11 2008 231 246
198. A. Tempestini, B. Caciagli, and M. Morganti Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules Oncol. Res. 16 2006 143 156
199. G. Toffoli, E. Cecchin, and G. Gasparini Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer J. Clin. Oncol. 28 2010 866 871
200. Y. Tokunaga, H. Sasaki, and T. Saito Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine Surgery 141 2007 346 353 (Pubitemid 46356434)
201. Y. Tong, X. Liu-Chen, and E.A. Ercikan-Abali Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells J. Biol. Chem. 273 1998 11611 11618 (Pubitemid 28272060)
202. A. Tumber, L.S. Collins, and K.D. Petersen The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo Cancer Chemother. Pharmacol. 60 2007 275 283 (Pubitemid 46742543)
203. C.M. Ulrich, J. Bigler, and C.M. Velicer Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene Cancer Epidemiol. Biomarkers Prev. 9 2000 1381 1385 (Pubitemid 32044809)
204. E. Van Cutsem, C.H. Kohne, and I. Lang Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J. Clin. Oncol. 29 2011 2011 2019
205. M. Van Engeland, S. Derks, K.M. Smits, G.A. Meijer, and J.G. Herman Colorectal cancer epigenetics: complex simplicity J. Clin. Oncol. 29 2011 1382 1391
206. C.J. Van Groeningen, A. Leyva, A.M. O'Brien, H.E. Gall, and H.M. Pinedo Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients Cancer Res. 46 1986 4831 4836 (Pubitemid 16000370)
207. A.R. Van Rompay, M. Johansson, and A. Karlsson Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases Pharmacol. Ther. 87 2000 189 198
208. J. Vansteenkiste, E. Van Cutsem, and H. Dumez Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer Invest. New Drugs 26 2008 483 488
209. M. Vignoli, S. Nobili, and C. Napoli Thymidylate synthase expression and genotype have no major impact on theclinical outcome of colorectal cancer patients treated with 5-fluorouracil Pharmacol. Res. 64 2011 242 248
210. J. Viguier, V. Boige, and C. Miquel ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer Clin. Cancer Res. 11 2005 6212 6217 (Pubitemid 41262950)
211. E. Vilar, and S.B. Gruber Microsatellite instability in colorectal cancer-the stable evidence Nat. Rev. Clin. Oncol. 7 2010 153 162
212. E. Vilar, M. Scaltriti, and J. Balmana Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines Br. J. Cancer 99 2008 1607 1612
213. C.G. Wang, Y.J. Ye, and J. Yuan EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis World J. Gastroenterol. 16 2010 2421 2427
214. T.L. Wang, L.A. Diaz Jr., and K. Romans Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients Proc. Natl. Acad. Sci. U.S.A. 101 2004 3089 3094 (Pubitemid 38327739)
215. R.G. Watson, F. Muhale, and L.B. Thorne Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy Eur. J. Cancer 46 2010 3358 3364
216. W. Weber Cancer epigenetics Prog. Mol. Biol. Transl. Sci. 95 2010 299 349
217. D.J. Weisenberger, K.D. Siegmund, and M. Campan CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat. Genet. 38 2006 787 793 (Pubitemid 43980599)
218. A.J. Weiss, G.E. Metter, and T.F. Nealon Phase II study of 5-azacytidine in solid tumors Cancer Treat. Rep. 61 1977 55 58 (Pubitemid 8100657)
219. J.L. Westra, H. Hollema, and M. Schaapveld Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients Ann. Oncol. 16 2005 1646 1653 (Pubitemid 41510139)
220. R.P. Whitehead, C. Rankin, and P.M. Hoff Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) Invest. New Drugs 27 2009 469 475
221. P.M. Wilson, A. El-Khoueiry, and S. Iqbal A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy Cancer Chemother. Pharmacol. 65 2010 979 988
222. T.R. Wilson, P.G. Johnston, and D.B. Longley Anti-apoptotic mechanisms of drug resistance in cancer Curr. Cancer Drug Targets 9 2009 307 319
223. J.T. Wu, S.Y. Archer, B. Hinnebusch, S. Meng, and R.A. Hodin Transient vs. prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and apoptosis Am. J. Physiol. Gastrointest. Liver Physiol. 280 2001 G482 G490
224. Y. Yanagisawa, F. Maruta, and N. Iinuma Modified Irinotecan/5FU/ Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes Scand. J. Gastroenterol. 42 2007 477 484 (Pubitemid 46569407)
225. M.B. Yin, S.F. Zakrzewski, and M.T. Hakala Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil Mol. Pharmacol. 23 1983 190 197 (Pubitemid 13184506)
226. S. Yokoo, S. Masuda, A. Yonezawa, T. Terada, T. Katsura, and K. Inui Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer Drug Metab. Dispos. 36 2008 2299 2306
227. A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K. Inui Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family) J. Pharmacol. Exp. Ther. 319 2006 879 886
228. B.K. Yoo, R. Gredler, and N. Vozhilla Identification of genes conferring resistance to 5-fluorouracil Proc. Natl. Acad. Sci. U.S.A. 106 2009 12938 12943
229. J. Yu, R. Miller, and W. Zhang Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers Pharmacogenomics 9 2008 1459 1466
230. J. Yu, Z. Wang, K.W. Kinzler, B. Vogelstein, and L. Zhang PUMA mediates the apoptotic response to p53 in colorectal cancer cells Proc. Natl. Acad. Sci. U.S.A. 100 2003 1931 1936 (Pubitemid 36254551)
231. L. Zhang, J. Yu, B.H. Park, K.W. Kinzler, and B. Vogelstein Role of BAX in the apoptotic response to anticancer agents Science 290 2000 989 992
232. S. Zhang, K.S. Lovejoy, and J.E. Shima Organic cation transporters are determinants of oxaliplatin cytotoxicity Cancer Res. 66 2006 8847 8857 (Pubitemid 44449203)